A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer

Tas, FARUK; Guney, PINAR; Derin, Duygu; Aydiner, Adnan; Topuz, Erkan

doi:10.1007/s10147-007-0740-4

A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer

Tas F., Guney N., Derin D., Aydiner A., Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.2, pp.156-160, 2008 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 13 Issue: 2
Publication Date: 2008
Doi Number: 10.1007/s10147-007-0740-4
Journal Name: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.156-160
Istanbul University Affiliated: Yes

Abstract

Background. Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients.